Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LK101 monotherapy in advanced solid tumors
NCT06054932Phase 1Recruiting
- Sponsor
- Likang Life Sciences
- Start
- Sep 2023
- Primary completion
- Dec 2025
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of LK101 in solid tumor (advanced stage) (2 arms), sponsored by Likang Life Sciences. Primary endpoints: Dose Limiting Toxicity, Adverse Events and 3 more. Started Sep 2023; status: recruiting.
02
Drugs
LK101
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06054932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06054932.